Lung Cancer Clinical Trial

Pemetrexed Plus Gemcitabine for Patients With Locally Advanced or Metastatic NSCLC Who Have Not Had Previous Chemotherapy.

Summary

The purposes of this study are to determine:

The safety of pemetrexed plus Gemcitabine and any side effects that might be associated with the combination of these two drugs.
Whether pemetrexed plus Gemcitabine can help patients with non-small cell lung cancer live longer.
Whether pemetrexed plus Gemcitabine can make the tumor smaller or disappear, and for how long.
To see if patients feel better while taking pemetrexed plus Gemcitabine.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosis of Non-Small Cell Lung Cancer that can be treated with chemotherapy
Have received no prior chemotherapy for Non-Small Cell Lung Cancer
Have at least one measurable lesion
Have an adequate performance status
Sign an informed consent

Exclusion Criteria:

A female who is pregnant or breastfeeding
Treatment with an investigational drug within the last 30 days, previously completed or withdrawn from this study or any other study investigating pemetrexed
Treatment with radiation therapy within the last 1-2 weeks
Brain metastasis that is uncontrolled
Active infection or other serious condition

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

48

Study ID:

NCT00061464

Recruitment Status:

Completed

Sponsor:

Eli Lilly and Company

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Miami Florida, , United States
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Chicago Illinois, , United States
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Shreveport Louisiana, , United States
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Columbia South Carolina, , United States

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

48

Study ID:

NCT00061464

Recruitment Status:

Completed

Sponsor:


Eli Lilly and Company

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider